Scientists from Duke University (NC, USA) have identified the biological mechanisms underlying non-responsiveness to interferon-beta treatment for multiple sclerosis (MS) using an animal model of the disease. Interferon-beta is currently the standard treatment drug for MS; however, it has several drawbacks, including cost, side effects and lack of efficacy in some patients. These new findings have been published in Nature Neuroscience and could lead to the development of alternative drug treatments for MS patients for whom interferon-beta does not work.
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.